Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment
Top Cited Papers
Open Access
- 30 November 2019
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (12), 2091
- https://doi.org/10.3390/jcm8122091
Abstract
Clinical studies, as well as in vitro and in vivo experiments have demonstrated that byproducts from joint replacements induce an inflammatory reaction that can result in periprosthetic osteolysis (PPOL) and aseptic loosening (AL). Particle-stimulated macrophages and other cells release cytokines, chemokines, and other pro-inflammatory substances that perpetuate chronic inflammation, induce osteoclastic bone resorption and suppress bone formation. Differentiation, maturation, activation, and survival of osteoclasts at the bone–implant interface are under the control of the receptor activator of nuclear factor kappa-Β ligand (RANKL)-dependent pathways, and the transcription factors like nuclear factor κB (NF-κB) and activator protein-1 (AP-1). Mechanical factors such as prosthetic micromotion and oscillations in fluid pressures also contribute to PPOL. The treatment for progressive PPOL is only surgical. In order to mitigate ongoing loss of host bone, a number of non-operative approaches have been proposed. However, except for the use of bisphosphonates in selected cases, none are evidence based. To date, the most successful and effective approach to preventing PPOL is usage of wear-resistant bearing couples in combination with advanced implant designs, reducing the load of metallic and polymer particles. These innovations have significantly decreased the revision rate due to AL and PPOL in the last decade.Keywords
Funding Information
- Ministry of health of Czech republic (VES16-31852A)
- National Institutes of Health (R01AR055650, R01AR063717, R01AR073145, R01AR072613)
This publication has 184 references indexed in Scilit:
- Extracellular Matrix Degradation and Tissue Remodeling in Periprosthetic Loosening and Osteolysis: Focus on Matrix Metalloproteinases, Their Endogenous Tissue Inhibitors, and the ProteasomeBioMed Research International, 2013
- Effect of a CCR1 receptor antagonist on systemic trafficking of MSCs and polyethylene particle-associated bone lossBiomaterials, 2012
- Osteoclast fusion and regulation by RANKL-dependent and independent factorsWorld Journal of Orthopedics, 2012
- Biological responses of human mesenchymal stem cells to titanium wear debris particlesJournal of Orthopaedic Research, 2011
- Selective inhibition of the MCP‐1‐CCR2 ligand‐receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particlesJournal of Orthopaedic Research, 2011
- Fluid pressure and flow as a cause of bone resorptionActa Orthopaedica, 2010
- Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysisMolecular Immunology, 2009
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Foreign body reaction to biomaterialsSeminars in Immunology, 2007
- Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapiesArthritis Research & Therapy, 2007